• News
  • SAN DIEGO
  • BioTech

Ligand inks deal with Omthera Pharma

San Diego-based Ligand Pharmaceuticals (Nasdaq: LGND) has signed a licensing agreement and research collaboration with Omthera Pharmaceuticals, a wholly-owned subsidiary of AstraZeneca (NYSE: AZN), for the development of products to treat dyslipidemia, a high concentration of cholestorol, fat or other lipids in the blood.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11085 N. Torrey Pines Rd. Ste., 300
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
55.27
  0.90  
+ 1.66%
359,983,000
80.42
41.99

Insider Trade Data

Date Insider Shares Type Value
10/15/2014 Kozarich, John W 2,000 Purchase $91,360
10/15/2014 Kozarich, John W 2,000 Purchase $91,360
10/13/2014 Foehr, Matthew W 1,000 Exchange $9,970
10/13/2014 Foehr, Matthew W 1,000 Exchange $9,970
10/10/2014 Foehr, Matthew W 85 Purchase $3,817

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
Subscribe Today!